Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
In postmortem Alzheimer’s disease brain sections, flortaucipir binds anterior cingulate tau with IC50 2.91 nM versus MK-6240 at 5.99 nM.
- Why it matters: Tau imaging agents need validated binding performance across Alzheimer’s disease and related conditions, including assessing whether flortaucipir shows off-target binding.
- What they did: Using [125I]IPPI, binding affinity was measured in AD anterior cingulate; [18F]flortaucipir binding was then compared across AD, Down syndrome, and cognitively normal brains, with [18F]MK-6240 and off-target checks in cognitively normal and Parkinson’s disease.
- The result: [18F]flortaucipir showed high gray-matter binding in AD and Down syndrome, with DSAD/CN ratios 15.7 (FCX) and 15.2 (TCX), and AD/CN ratios 12.4 (FCX) and 9.5 (TCX); it showed no off-target binding to MAO-A in CN and PD.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- Open access
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.